The Antifibrinolytic Drugs Market size was estimated at $13.59 billion in 2018 and is expected to hit at $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. The report provides a detailed analysis of the market size & estimations, top investment pockets, top winning strategies, drivers & opportunities, competitive scenario, and wavering market trends.
Request Sample Report at:
https://www.alliedmarketresearch.com/request-sample/6279
Increase in road accidents and improvement in surgical procedures drive the growth of the global antifibrinolytic drugs market. On the other hand, high cost of these drugs impedes the growth to some extent. However, untapped potential in developing countries is anticipated to pave the way for several opportunities in the near future.
Leading market players –
The key market players analyzed in the global antifibrinolytic drugs market include Xanodyne Pharmaceuticals, Akorn, Takeda, Amerigen Pharms Ltd, Mylan, Acic Fine Chems, Pfizer (GenMed), Sanofi, Zydus Cadila, and Aurobindo Pharma Ltd. They have incorporated a number of strategies including partnership, expansion, collaboration, joint ventures, and others to heighten their stand in the industry.
Antifibrinolytic is the class of drugs that is widely used to inhibit fibrinolysis by stopping activation of the proenzyme plasminogen to plasmin. This intrusion is crucial for averting clot degradation in areas rich in the fibrinolysis prone areas such as oral cavity, nasal cavity, and female reproductive tract. Approved antifibrinolytic drugs include Epsilon aminocaproic acid, Tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. In addition, these drugs find their application in surgeries such as cardiovascular surgeries, neurosurgeries, and dental surgeries. Furthermore, antifibrinolytic drugs are used by women to control heavy menstrual flow.
For Purchase Enquiry at:
https://www.alliedmarketresearch.com/purchase-enquiry/6279
Considerable increase in road accidents, rise in medical surgeries including cardiac, and dental, and surge in prevalence of angioedema are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a vital role in averting clot lysis and thereby, blood loss.
The antifibrinolytic drugs market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for most of the Antifibrinolytics Drug Market share in 2018, and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of these drugs by women to control heavy menstrual flow. Moreover, significant surge in surgeries in this region propels the market growth. However, the Asia-Pacific region is anticipated to grow at the fastest rate due to surge in road accidents and increased usage of these drugs by women to control heavy menstrual flow.
Speak With Analyst:
https://www.alliedmarketresearch.com/connect-to-analyst/6279
Key Findings of the Study:
- By indication, the gynecology segment accounted for the highest Antifibrinolytics Drug Market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
- By region, North America was the major shareholder and accounted for the highest share of 42% in 2018.
- Asia-Pacific is expected to grow at a CAGR of 6.1% during the forecast period.
- By end user, the hospital & clinics segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com